<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although hyperdynamic therapy is an accepted method of treatment of patients with symptomatic <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo>, it remains unproven in large scale trials and controlled studies </plain></SENT>
<SENT sid="1" pm="."><plain>Furthermore, methods of hyperdynamic therapy and specific endpoints vary widely </plain></SENT>
<SENT sid="2" pm="."><plain>A systematic review of clinical trials of the various techniques of hyperdynamic therapy and their effects on cerebral blood flow found only 11 studies suitable for analysis </plain></SENT>
<SENT sid="3" pm="."><plain>Although controlled trials are lacking, there is some evidence to suggest that <z:hpo ids='HP_0000822'>hypertension</z:hpo> is the most promising component of hyperdynamic therapy </plain></SENT>
<SENT sid="4" pm="."><plain>These findings support a future randomized trial of induced <z:hpo ids='HP_0000822'>hypertension</z:hpo> in patients with symptomatic <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
</text></document>